Top section
Top section
Transition finance in transition — companies face investors in flux
Demand to invest in the low carbon transition is growing fast, but strategies are very diverse
Issuance net of buy-backs is not that high, and there is no sign of any indigestion
Caffil lands social covered bond as market ‘comes off the boil’
◆ Order book smaller than issuer’s last covered in January ◆ Banker said covered bond market has reached plateau ◆
Issuance net of buy-backs is not that high, and there is no sign of any indigestion
Sub-sections
-
Treasury director Rodrigo Robledo says investor relations work has paid off -
◆ Two steps to terms debated ◆ Priced flat to fair value or even with negative concession ◆ Investors split on long-dated holdco supply
-
◆ Norwegian bank increases size ◆ Issuer meets spread objective ◆ Banker said he drew confidence from secondaries
-
◆ Issuers opt for extra guidance as market softens ◆ Enexis takes size at six years ◆ DSM-Firmenich lands tight
-
◆ Madrid plans 10 year deal ◆ Bpifrance set to launch EuGB ◆ MuniFin 'rare and well regarded'
-
This week's flurry of deals takes year to date volume beyond £8bn
-
Shipbuilder's shares fall 10% after capital raise
-
◆ Energy pair bring three tranches ◆ Sub-100bp senior/hybrid spreads secured ◆ Single digit concessions offered
-
Founder of climate investing think tank wants to apply ideas as bond investor
-
When loans' LTVs hit 80%, Bitcoin stakes are liquidated in seconds
-
-
Latest issue rides on coattails of big tech investment spree
-
Ivory Coast squeezed tight, taking $1.3bn in an 'aggressive' execution
-
Blackstone is targeting a quicker than usual three day execution
-
The country is one of the highest regarded sovereign issuers on the continent
-
The government has been much more proactive in its debt management since a scare in 2024
-
The yield was ultra high but Congo had little room to manoeuvre
-
Benin showed Islamic issuance is a viable market for sub-Saharan African sovereigns
-
When the stakes are high, a small change in odds merits a big reaction
-
-
Craig Coben examines whether it is true that no good deed goes unpunished
-
Investors have got a fever, and the only cure is more pharma. Biotech equity issuance is surging, in line with rising stock prices in the secondary market, as stock pickers pan for the company that will cure Covid-19, among other maladies. But this is more speculating than investing and many are going to catch a cold chasing around a risky sector that is starting to look a lot like the dot-com bubble.
-
Freeline Theraputics, the UK gene therapeutics company, has filed to list in the US on the Nasdaq exchange, continuing the trend of biotech companies seeking to raise capital in the equity capital markets.
-
The Covid-19 pandemic is forcing many governments to expand their borrowing programmes. The table below details the impact of the outbreak on the funding requirements of major sovereign bond issuers.
-
Sponsored by Islamic Development Bank (IsDB)
Sukuk market’s next chapter: Financing the future, sustainably
-
-
Sponsored by CAF – Development Bank of Latin America and the Caribbean
CAF gearing up to transform regional development
-
Sponsored by Emirates NBD Capital
Emirates NBD Capital: An unrivalled conduit for Middle East liquidity
